MAPT and Alzheimer disease: Nanomolar concentrations of soluble Aβ peptides extracted from the brain of AD patients have been shown to enhance tau pathology in mouse hippocampal neurons, and subsequently to compromise synaptic structure and function, suggesting a synergistic effect of Aβ and tau in neurodegeneration [6].